A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children.
<h4>Unlabelled</h4>In the Sahel, most malaria deaths occur among children 1-4 years old during a short transmission season. A trial of seasonal intermittent preventive treatment (IPT) with sulfadoxine-pyrimethamine (SP) and a single dose of artesunate (AS) showed an 86% reduction in the...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2008-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0001471&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849387106279882752 |
|---|---|
| author | Cheikh Sokhna Badara Cissé El Hadj Bâ Paul Milligan Rachel Hallett Colin Sutherland Oumar Gaye Denis Boulanger Kirsten Simondon François Simondon Geoffrey Targett Jo Lines Brian Greenwood Jean-François Trape |
| author_facet | Cheikh Sokhna Badara Cissé El Hadj Bâ Paul Milligan Rachel Hallett Colin Sutherland Oumar Gaye Denis Boulanger Kirsten Simondon François Simondon Geoffrey Targett Jo Lines Brian Greenwood Jean-François Trape |
| author_sort | Cheikh Sokhna |
| collection | DOAJ |
| description | <h4>Unlabelled</h4>In the Sahel, most malaria deaths occur among children 1-4 years old during a short transmission season. A trial of seasonal intermittent preventive treatment (IPT) with sulfadoxine-pyrimethamine (SP) and a single dose of artesunate (AS) showed an 86% reduction in the incidence of malaria in Senegal but this may not be the optimum regimen. We compared this regimen with three alternatives.<h4>Methods</h4>2102 children aged 6-59 months received either one dose of SP plus one dose of AS (SP+1AS) (the previous regimen), one dose of SP plus 3 daily doses of AS (SP+3AS), one dose of SP plus three daily doses of amodiaquine (AQ) (SP+3AQ) or 3 daily doses of AQ and AS (3AQ+3AS). Treatments were given once a month on three occasions during the malaria transmission season. The primary end point was incidence of clinical malaria. Secondary end-points were incidence of adverse events, mean haemoglobin concentration and prevalence of parasites carrying markers of resistance to SP.<h4>Findings</h4>The incidence of malaria, and the prevalence of parasitaemia at the end of the transmission season, were lowest in the group that received SP+3AQ: 10% of children in the group that received SP+1AS had malaria, compared to 9% in the SP+3AS group (hazard ratio HR 0.90, 95%CI 0.60, 1.36); 11% in the 3AQ+3AS group, HR 1.1 (0.76-1.7); and 5% in the SP+3AQ group, HR 0.50 (0.30-0.81). Mutations associated with resistance to SP were present in almost all parasites detected at the end of the transmission season, but the prevalence of Plasmodium falciparum was very low in the SP+3AQ group.<h4>Conclusions</h4>Monthly treatment with SP+3AQ is a highly effective regimen for seasonal IPT. Choice of this regimen would minimise the spread of drug resistance and allow artemisinins to be reserved for the treatment of acute clinical malaria. |
| format | Article |
| id | doaj-art-cc112bee4bd141e98a5a66827e941d16 |
| institution | Kabale University |
| issn | 1932-6203 |
| language | English |
| publishDate | 2008-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-cc112bee4bd141e98a5a66827e941d162025-08-20T03:55:22ZengPublic Library of Science (PLoS)PLoS ONE1932-62032008-01-0131e147110.1371/journal.pone.0001471A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children.Cheikh SokhnaBadara CisséEl Hadj BâPaul MilliganRachel HallettColin SutherlandOumar GayeDenis BoulangerKirsten SimondonFrançois SimondonGeoffrey TargettJo LinesBrian GreenwoodJean-François Trape<h4>Unlabelled</h4>In the Sahel, most malaria deaths occur among children 1-4 years old during a short transmission season. A trial of seasonal intermittent preventive treatment (IPT) with sulfadoxine-pyrimethamine (SP) and a single dose of artesunate (AS) showed an 86% reduction in the incidence of malaria in Senegal but this may not be the optimum regimen. We compared this regimen with three alternatives.<h4>Methods</h4>2102 children aged 6-59 months received either one dose of SP plus one dose of AS (SP+1AS) (the previous regimen), one dose of SP plus 3 daily doses of AS (SP+3AS), one dose of SP plus three daily doses of amodiaquine (AQ) (SP+3AQ) or 3 daily doses of AQ and AS (3AQ+3AS). Treatments were given once a month on three occasions during the malaria transmission season. The primary end point was incidence of clinical malaria. Secondary end-points were incidence of adverse events, mean haemoglobin concentration and prevalence of parasites carrying markers of resistance to SP.<h4>Findings</h4>The incidence of malaria, and the prevalence of parasitaemia at the end of the transmission season, were lowest in the group that received SP+3AQ: 10% of children in the group that received SP+1AS had malaria, compared to 9% in the SP+3AS group (hazard ratio HR 0.90, 95%CI 0.60, 1.36); 11% in the 3AQ+3AS group, HR 1.1 (0.76-1.7); and 5% in the SP+3AQ group, HR 0.50 (0.30-0.81). Mutations associated with resistance to SP were present in almost all parasites detected at the end of the transmission season, but the prevalence of Plasmodium falciparum was very low in the SP+3AQ group.<h4>Conclusions</h4>Monthly treatment with SP+3AQ is a highly effective regimen for seasonal IPT. Choice of this regimen would minimise the spread of drug resistance and allow artemisinins to be reserved for the treatment of acute clinical malaria.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0001471&type=printable |
| spellingShingle | Cheikh Sokhna Badara Cissé El Hadj Bâ Paul Milligan Rachel Hallett Colin Sutherland Oumar Gaye Denis Boulanger Kirsten Simondon François Simondon Geoffrey Targett Jo Lines Brian Greenwood Jean-François Trape A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. PLoS ONE |
| title | A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. |
| title_full | A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. |
| title_fullStr | A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. |
| title_full_unstemmed | A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. |
| title_short | A trial of the efficacy, safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in Senegalese children. |
| title_sort | trial of the efficacy safety and impact on drug resistance of four drug regimens for seasonal intermittent preventive treatment for malaria in senegalese children |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0001471&type=printable |
| work_keys_str_mv | AT cheikhsokhna atrialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT badaracisse atrialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT elhadjba atrialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT paulmilligan atrialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT rachelhallett atrialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT colinsutherland atrialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT oumargaye atrialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT denisboulanger atrialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT kirstensimondon atrialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT francoissimondon atrialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT geoffreytargett atrialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT jolines atrialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT briangreenwood atrialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT jeanfrancoistrape atrialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT cheikhsokhna trialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT badaracisse trialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT elhadjba trialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT paulmilligan trialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT rachelhallett trialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT colinsutherland trialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT oumargaye trialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT denisboulanger trialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT kirstensimondon trialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT francoissimondon trialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT geoffreytargett trialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT jolines trialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT briangreenwood trialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren AT jeanfrancoistrape trialoftheefficacysafetyandimpactondrugresistanceoffourdrugregimensforseasonalintermittentpreventivetreatmentformalariainsenegalesechildren |